Summary
79 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 40 USD is left as net profit.
- Revenue grew by 1,533% a year over the last 3 years.
- It earns 28 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $38.9M against $2.65M.
What to watch
- Earnings per share fell by 81% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
Revenue grew by 467% a year over 5 years. Over the last 3 years it grew by 1,533% a year. Earnings per share fell by 81% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 57 USD
- Research and development 4.3 USD
- Sales and administration 14 USD
- Taxes and other -15 USD
- Net profit 40 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 40 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Manufacturing 99%
- Licensing 0.7%
By region
The company reports no revenue by region.
Manufacturing brings in 99% of revenue.
Segments in detail